Liver cancer: time to evolve trial design after everolimus failure

Area of Science:

• Hepatobiliary cancers
• Oncology
• Clinical trials

Background:

• Hepatocellular carcinoma (HCC) is a challenging malignancy with limited therapeutic options.
• Sorafenib is the current standard of care for advanced HCC, but its efficacy is modest.
• Numerous kinase inhibitors have failed to demonstrate significant benefit in phase III trials.

Purpose of the Study:

• To evaluate the efficacy of everolimus as a second-line treatment for advanced hepatocellular carcinoma.
• To assess the impact of everolimus on patient outcomes in a previously treated HCC population.

Main Methods:

• The EVOLVE-1 trial was a phase III study.
• Patients with advanced hepatocellular carcinoma received second-line treatment with everolimus.
• Key endpoints included overall survival and progression-free survival.

Main Results:

• The EVOLVE-1 trial did not meet its primary endpoints.
• Everolimus demonstrated a lack of clinical benefit in the second-line treatment setting for advanced HCC.
• No significant improvement in survival was observed compared to placebo or standard care.

Conclusions:

• Everolimus is not effective as a second-line treatment for advanced hepatocellular carcinoma.
• The findings highlight the unmet need for novel therapeutic strategies in advanced HCC.
• Further research is needed to identify more effective treatments for this difficult-to-treat cancer.